Cetilistat ATL-962 Powder CAS 282526-98-1 Raw Material

CAS:282526-98-1 

MF: C25H39NO3

MW:401.58

EINECS: 1308068-626-2

Specification​: 99% min Cetilistat 

Sample: Cetilistat Powder

Brand: Henrikang

Appearance: White Powder

Storage: Cool Dry Place

Shelf Life: 2 Years

Test Method: HPLC

Portal:https://henrikang.en.made-in-china.com/

Cetilistat Powder Usage and Synthesis.

Cetilistat Powder (Cetilistat, ATL-962), also known as Cetilistat, is a new gastrointestinal lipase inhibitor, Cetilistat CAS 282526-98-1 is a novel pancreatic lipase inhibitor for the treatment of obesity in diabetic and non-diabetic patients. 

Cetilistat Raw Material is also called Cetilistat, Cellistat, Cetilistat, Cetilistat Raw Material white to white crystalline Powder, easy to dissolve in methanol, Cetilistat powder main uses: new weight loss medicine, and can be used in smoking cessation; Indications: new weight loss, smoking cessation, blood lipid reduction, pharmaceutical raw materials.

Application/Function of Cetilistat Powder.

Cetilistat (also known as ATL-962) was approved in September 2013 by the Japanese Ministry of Health, Labor and Welfare for the treatment of obesity, limited to patients with both type 2 diabetes mellitus (T2DM) and dyslipidemia, and with a body mass index (BMI)25 kg/m2 in spite of dietary treatment and/or exercise therapy. 

The medicinal chemistry program has not been described in the scientific literature, but the patent describing cetilistat also describes the synthesis of analogs with varied aryl substituents and lipophilic tails. The synthesis of cetilistat involves condensation of a hexadecylcarbonochloridate with 2-amino-5-methylbenzoic acid; other analogs were synthesized by varying the carbonochloridate and 2-aminobenzoic acid components. 

Cetilistat is a potent inhibitor of human and rat pancreatic lipase with IC50s of 15 and 136 nM, respectively, with little inhibition of trypsin or chymotrypsin.

Pharmacological Effects of Cetilistat Powder

Neolistat is a long-acting and potent inhibitor of specific gastrointestinal lipase that acts as a therapeutic agent by forming covalent bonds with the active serine sites of gastric and pancreatic lipase in the stomach and small intestine to inactivate enzymes that are unable to hydrolyze food fats, primarily triglycerides, into absorbable free fatty acids and monacylglycerol. Undigested triglycerides cannot be absorbed by the body, reducing calorie intake and controlling weight.